Larvol Veri

BIOMARKER:

VHL mutation

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VHL mutation VHL mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	MK-6482 Sensitive: C2 – Inclusion Criteria MK-6482 Sensitive : C2
VHL mutation VHL mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	PT2385 Sensitive: C2 – Inclusion Criteria PT2385 Sensitive : C2
VHL mutation VHL mutation	Neuroendocrine Tumor Neuroendocrine Tumor	PT2385 Sensitive: C3 – Early Trials PT2385 Sensitive : C3
VHL mutation VHL mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
VHL mutation VHL mutation	Renal Cell Carcinoma RCC	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
VHL mutation VHL mutation	Cholangiocarcinoma Cholangiocarcinoma	sunitinib Sensitive: C4 – Case Studies sunitinib Sensitive : C4
VHL mutation VHL mutation	Renal Cell Carcinoma RCC	doxorubicin hydrochloride Sensitive: D – Preclinical doxorubicin hydrochloride Sensitive : D